Clover Health Investments (CLOV) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clover Health Investments in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CLOV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLOV, but not buy additional shares or sell existing shares.
View CLOV analyst ratings or view top-rated stocks.

4 analysts have issued twelve-month price targets for Clover Health Investments' stock. Their CLOV share price forecasts range from $1.00 to $4.00. On average, they expect the company's share price to reach $2.08 in the next twelve months. This suggests a possible upside of 104.2% from the stock's current price.
View analysts price targets for CLOV or view top-rated stocks among Wall Street analysts.

Clover Health Investments' stock was trading at $0.9295 at the start of the year. Since then, CLOV shares have increased by 9.7% and is now trading at $1.02.
View the best growth stocks for 2023 here.

Clover Health Investments saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 37,550,000 shares, a drop of 5.7% from the April 30th total of 39,820,000 shares. Based on an average daily volume of 6,700,000 shares, the days-to-cover ratio is currently 5.6 days.
View Clover Health Investments' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CLOV earnings forecast.

ETFs with the largest weight of Clover Health Investments (NASDAQ:CLOV) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Janus Henderson Small Cap Growth Alpha ETF (JSML), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), iShares U.S. Healthcare Providers ETF (IHF),

Clover Health Investments updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.93 billion-$2.03 billion, compared to the consensus revenue estimate of $1.95 billion.

Clover Health Investments trades on the NASDAQ under the ticker symbol "CLOV."

Clover Health Investments' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.55%), State Street Corp (1.84%), Geode Capital Management LLC (1.44%), Renaissance Technologies LLC (1.43%), Charles Schwab Investment Management Inc. (0.50%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Chamath Palihapitiya, Chelsea Clinton and Lee Shapiro.
View institutional ownership trends.

Shares of CLOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLOV stock can currently be purchased for approximately $1.02.

Clover Health Investments (NASDAQ:CLOV) has a market capitalization of $492.30 million and generates $3.48 billion in revenue each year. The company earns $-338,840,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

The company employs 680 workers across the globe.

Clover Health Investments' mailing address is 317 University Ave Suite 200, Palo Alto CA, 94301. The official website for the company is www.cloverhealth.com. The company can be reached via phone at 201-432-2133 or via email at investors@cloverhealth.com.